Tiziana Life Sciences PLC (TLSA): Price Target Chart
Tiziana Life Sciences (TLSA) develops advanced therapies for immune and neurological pathologies. This chart illustrates the price action of an asset whose valuation is driven by exclusive antibody delivery patents. The business focuses on the nasal administration of Foralumab to combat multiple sclerosis by bypassing the bloodstream. The current metric stands at 7.97, while funds are being allocated to the clinic, which temporarily nullifies operational scalability.
Analytical breakdowns for Tiziana Life Sciences PLC (TLSA)
- stock quotes and analyst forecast:
- stock exchange capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity Tiziana Life Sciences|TLSA - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Tiziana Life Sciences, Ltd.|TLSA - Company Aggregate Debts|Debts to Book Capitalization Tiziana Life Sciences PLC|TLSA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Tiziana Life Sciences|Quick Liquidity Indicator tizianalifesciences.com
- net income and valuation ratios data:
TLSA - Net Profit|Projected Future Earnings Tiziana Life Sciences|TLSA - Price to Earnings Ratio|Future Price to Earnings Multiple Tiziana Life Sciences Ltd.|TLSA - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Tiziana Life Sciences PLC|TLSA - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Tiziana Life Sciences|TLSA - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months tizianalifesciences.com|TLSA - Net earnings per share growth this year|Earnings growth forecast for next year Tiziana Life Sciences
- issuer revenue and sales details:
General company analysis:TLSA tizianalifesciences.com
This indicator represents the weighted average of target prices from leading investment banks, promptly reflecting the revaluation of the business's fundamental value between quarterly reports. By analyzing the aggregated share price forecast, investors identify trend reversal points, which for Tiziana Life Sciences (TLSA) often correlate with the efficiency of biomedical logistics during the delivery of antibodies to laboratories.
Competitors of Tiziana Life Sciences
Analyst Forecast Prices ARGX|Price Target Chart BioNTech BNTX|Abivax SA - Price Target Chart|ADMA - Price Target Chart|Analyst Median Target Protagonist Corp PTGX|IMVT: Analyst Consensus Forecast|kiniksa.com (KNSA) - Analyst Consensus Forecast|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|JBIO: Consensus Target|Aclaris Therapeutics, Inc - Analyst Forecast Prices|KYTX: Analyst Consensus Forecast|CABA - Analyst Median Target|Consensus Target VTYX|Theratechnologies, Inc. - Forecast Levels Chart|Analyst Consensus Forecast AVTX|Analyst Median Target Eledon Pharmaceuticals, Inc|Analyst Consensus Forecast AGEN (Agenus)|Analyst Consensus Forecast climbbio.com CLYM|ZURA - Price Target Chart|ATYR (aTyr Pharma Inc) - Broker Consensus Forecast|ADAG: Analyst Consensus Forecast|Ikena Oncology (IMA) - Analyst Consensus Forecast|Consensus Target STTK|EQ: Fair Value Consensus|Price Target Chart Connect Biopharma (CNTB)|Price Target Chart IMUX (immunic-therapeutics.com)|Analyst Consensus Forecast ATRA (Atara Bio)|Analyst Median Target InflaRx NV (IFRX)|X4 Pharmaceuticals - Analyst Consensus Forecast|Forecast Levels Chart ACET|CELU: Analyst Consensus Forecast|Average Forecast Price INmune Bio Inc (INMB)|Consensus Target BRNS|KZR: Fair Value Consensus|Price Target Chart SAB Biotherapeutics (SABS)|Analyst Median Target akaritx.com|Analyst Consensus Forecast ENLV (Enlivex Therapeutics Ltd.)|QTTB - Consensus Target|GeoVax Labs Inc - Analyst Consensus Forecast|Analyst Median Target Edesa Biotech Corp EDSA|IBIO: Analyst Consensus Forecast|Average Forecast Price Carisma Therapeutics Inc. (CARM)|Price Target Chart XTL Biopharmaceuticals Ltd.|Broker Consensus Forecast BOLT (Bolt Bio)|Analyst Consensus Forecast HCWB|Consensus Target aptevotherapeutics.com APVO|Analyst Consensus Forecast AIM (AIM ImmunoTech)|Aditxt Inc. (ADTX) - Average Forecast Price|GRI - Price Target Chart|Analyst Median Target XORTX Therapeutics Inc XRTX|HIND (ReShape Lifesciences) - Consensus Target|REVB: Analyst Forecast Prices|Price Target Chart Indaptus Therapeutics|Price Target Chart SCNI|Price Target Chart CalciMedica, Inc. (CALI)|Analyst Median Target affimed.com|Analyst Consensus Forecast ALLK (Allakos)|Analyst Consensus Forecast HOOKIPA Pharma, Inc. HOOK|IGMS - Price Target Chart|Forecast Levels Chart ITOS|OCEA: Analyst Consensus Forecast|TC BioPharm (Holdings) Plc - Fair Value Consensus|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
